Tempest <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Suspends Prospectus Supplement, Halts Securities Sales Under Jefferies Agreement
Tempest Therapeutics Inc. has announced the suspension and termination of its prospectus supplement, originally filed on February 6, 2025, related to the company's common stock issuable under the Open Market Sale Agreement with Jefferies LLC. The decision, communicated on June 11, 2025, halts any sales of securities under this agreement until a new prospectus or registration statement is filed. Despite this change, the Sales Agreement itself remains effective. Further details about the Sales Agreement can be found in the company's previous Form 8-K filing with the Securities and Exchange Commission on June 20, 2024.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempest Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-138802), on June 11, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。